Beta-NGF

Beta-NGF Molekülinformation

Englischer Name	Nerve growth factor	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	14	Target-Alias	Nerve Growth Factor
Höchste Forschungs- und Entwicklungsphase	NDA/BLA

Englischer Name	Nerve growth factor
Target-Alias	Nerve Growth Factor
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	14
Höchste Forschungs- und Entwicklungsphase	NDA/BLA

Beta-NGF Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (1)Mouse (1)
Etikett
Tag Free (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
BEF-H5214	Human	HEK293	Human Beta-NGF Protein, premium grade				In den Warenkorb legen
BEF-M5213	Mouse	HEK293	Mouse Beta-NGF Protein, Tag Free (MALS verified)				In den Warenkorb legen

Gesamtmenge2

Beta-NGF Molekülhintergrund

Nerve growth factor beta (beta-NGF) is a neurotrophic factor that plays critical role in the development and maintenance of sensory and sympathetic neurons. The active form of human beta-NGF is is a noncovalently disulfide-linked homodimer, which is secreted and signals through the low affinity nerve growth factor receptor (LNGFR) and the tropomyosin receptor kinase A (TrkA) to activate PI3K, Ras, and PLC signaling pathways.

Beta-NGF Molekülalias

NGF,NGFB,Beta-NGF,HSAN5,MGC161426,MGC161428

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
RGN-259	RGN-457; RGN-352; RGN-259; RGN-137; Tβ4; TB4; GBT-101; GBT-201; Thymosin beta 4-16-38; TB4 16-38; Thymosin beta4; Thymosin B4; Fx peptide	Phase 3 Clinical	National Institutes Of Health	Diabetes Mellitus; Dry Eye Syndromes; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Graft vs Host Disease; Keratitis; Myocardial Infarction; Myocardial Ischemia; Pressure Ulcer; Sjogren's Syndrome; ST Elevation Myocardial Infarction; Varicose Ulcer; Xerophthalmia	Details
Fasinumab	SAR-164877; MT-5547; R-475; REGN-475	Phase 3 Clinical	Regeneron Pharmaceuticals Inc	Abdominal Pain; Back Pain; Low Back Pain; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Sciatica	Details
SSS-40	SSS-40; SSS-40-anti-NGF Ab; SSS40 anti-NGF Ab	Phase 2 Clinical	3sbio Inc	Bone Neoplasms; Cancer Pain; Osteoarthritis	Details
SHR-2017	SHR-2017; SHR2017	Phase 2 Clinical	Suzhou Suncadia Biopharmaceuticals Co Ltd	Bone metastases; Multiple Myeloma; Osteoporosis; Solid tumours	Details
Antibodies to humanized nerve growth factor(Shenyang Sunshine Pharmaceutical)		Phase 2 Clinical	Shenyang Sunshine Pharmaceutical Co Ltd	Bone metastases; Cancer Pain	Details
EP-9001A	EP-9001A	Phase 2 Clinical	Chengdu Youluo Biotechnology Co Ltd	Bone metastases; Cancer Pain; Pain	Details
DS-002	DS-002	Phase 2 Clinical	Dartsbio Pharmaceuticals Ltd	Cancer Pain; Pain	Details
Atinumab	NG-101; ATI-355	Phase 2 Clinical	Novartis Pharma Ag	Diabetic Gastroparesis; Gastroparesis; Spinal Cord Injuries	Details
Luvagrobart	AK-115	Phase 1 Clinical		Cancer Pain; Pain	Details
4B03-04	4B03-04	Phase 1 Clinical	Fubei Biomedical Technology (Beijing) Co Ltd	Osteoarthritis	Details
DS-010	DS010; DS-010	Phase 1 Clinical	Dartsbio Pharmaceuticals Ltd	Cachexia	Details
TNM-009	TNM-009; TNM009	Phase 1 Clinical	Zhuhai Trinomab Pharmaceutical Co Ltd	Cancer Pain; Pain	Details
SMR-7694	SMR-7694; SMR7694	Phase 1 Clinical	Sinobioway Biomedicine Co Ltd	Osteoarthritis	Details
Neuroregenerative agents (iNtRON Biotechnology)		Clinical	Intron Biotechnology	Nervous System Diseases	Details